{
  "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
  "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
  "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 41,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide combines a biological pathway diagram with a clinical trial summary table to demonstrate clinical validation.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/11",
  "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
  "deckJsonHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549.json",
  "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.5,
        "y": 0.75
      },
      "kind": "callout",
      "text": "Total size of safety database > 500 patients (includes monotherapy and combinations)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "596a34db-50f1-4553-8851-86a141c26ccb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.35,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Biological pathway diagram showing Naporafenib, Trametinib, Rineterkib, and Ribociclib interactions.",
      "attrs": null,
      "subkind": "value-chain",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ae1e852-d4af-47ba-b4ec-1c3027c56a73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Novartis Non-Confidential Materials; PoC = proof-of-concept",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8584937-dc26-4246-9193-ff2d1f35ac13",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.56,
        "x": 0.41,
        "y": 0.338
      },
      "kind": "table",
      "text": "Study (Trial #) | Description | N\nPh 1 FIH study (LXH254X2101) | Naporafenib dose escalation... | 142\nPh 1b combo dose finding (LXH254X2102) | Dose-finding study... | 241\nPh 2 combo study (LXH254C12201) | Evaluating efficacy... | 134",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a3bbc0d8-7389-4ccf-a30a-3efd5a10475d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.96,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "Naporafenib has been dosed in more than 500 patients to date, establishing its safety, tolerability, and preliminary PoC in multiple indications",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88f0666e-2871-4607-a685-bbb37b093787",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 11,
      "beatId": "a76347f3-7542-420a-90ec-25e0eba8ea42",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence",
      "beatSlug": "evidence",
      "evidence": "Presenting data supporting the potential of naporafenib and ERAS-007",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 11,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "358fb471-d96f-4378-96a1-118dca13bdc4",
      "evidence": "The deck presents data supporting the potential of naporafenib and ERAS-007",
      "position": 1,
      "objective": "What are the potential benefits of investing in Erasca's pipeline?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}